Dianthus Therapeutics, Inc.
DNTH
Rang in aandelen
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aandeelprijs
$75.21
Marktkapitalisatie
$4.21B
Verandering (1 dag)
4.33%
Verandering (1 jaar)
110.98%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Categorie
Healthcare
P/S-ratio voor Dianthus Therapeutics, Inc. (DNTH)
P/S-ratio op October 2026 TTM: 2.20K
Volgens de meest recente financiële rapporten en aandelenkoers van Dianthus Therapeutics, Inc. is de huidige P/S-ratio (TTM) 2.20K. Eind 2023 had het bedrijf een P/S-ratio van 18.97.
P/S-ratiohistoriek voor Dianthus Therapeutics, Inc. van 2016 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 2.20K | 1,785.51% |
| 2024 | 116.48 | 514.17% |
| 2023 | 18.97 | 413.89% |
| 2022 | 3.69 | -97.76% |
| 2021 | 164.92 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | -99.54% |
US
|
|
| 40.55 | -98.15% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.54% |
NL
|
